Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference
Kuros Biosciences (“Kuros” or “the Company”), a leader in next generation bone graft technologies, today announced it wi…
Kuros Biosciences (“Kuros” or “the Company”), a leader in next generation bone graft technologies, today announced it wi…
. New level 1 data from the MAXA Clinical Trial comparing standalone MagnetOs to the gold standard autograft in the ch…
RMAT designation granted by FDA CBER for IMA203 cell therapy in multiple PRAME-expressing tumors including cutaneous…
Wissenschaftlerinnen und Wissenschaftler vom Deutschen Krebsforschungszentrum (DKFZ) und vom Cambridge Stem Cell Instit…
Research collaboration leverages bit.bio’s machine learning-powered discovery platform to identify transcription factor…
Update covers data from 11 heavily pre-treated, last-line patients in Phase 1b dose expansion Cohort A treated with IMA2…
MorphoSys U.S. Inc., eine hundertprozentige Tochtergesellschaft der MorphoSys AG (FSE: MOR; NASDAQ: MOR), und Incyte (Na…
Mit der Kombination der Medikamente Venetoclax und 5-Azacitidin steht seit einigen Jahren eine neue, effektive und vertr…
Rune Labs’ StriveStudy platform and Emerald Innovations’ Emerald wireless monitoring sensor will passively capture data…
Publications in peer reviewed Journal of Immunology and Regenerative Medicine and Clinical Oral Implants Research Adds…